WAVODYNE THERAPEUTICS

WavoDyne Therapeutics Inc. is a new company formed for the purpose of commercializing a group of novel small molecule therapeutics which have displayed exceptional potency in preclinical models for the treatment of memory and cognitive disorders resulting from neuroinflammatory processes. The Company’s product pipeline represents 20 years of innovative research which has been funded by $25 mm of various grants from the National Institute of Health. WavoDyne Therapeutics has entered into a lice... nsing transaction with the University of Rochester Medical Center, the site of preclinical research that generated the portfolio of clinical drug candidates. The license provides WavoDyne Therapeutics exclusivity on a series of patented novel drug candidates which have high selectivity for inhibition of the Mixed Lineage Kinases. The Company anticipates commencing a Phase 1 clinical study by 2Q2016 with its lead drug candidate, URMC-099, which will target the treatment of POCD ( Postoperative Cognitive Dysfunction ). Another Ph. 1 study with this drug candidate is planned to commence in 2016 for the treatment of HAND ( HIV Associated Neurocognitive Disorders ). The treatment of cognitive disorders associated with Multiple Sclerosis and Parkinson’s Disease also figure prominently in the Company’s project plans. Based on standard drug development timelines, regulatory requirements, and the timely completion of our pivotal clinical trials, WavoDyne expects to launch its first product for the treatment of POCD in the 2021-2022 timeframe.More